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Histone Deacetylase Inhibitors: Role in Gene Expression and Development of 
New Anticancer Drug Candidates 
Mohamed Ammar 
 
Abstract: 
 Histone deactylase (HDAC) suppresses gene expression by removing acetyl groups from 
lysine residues in chromatin.  Inhibitors play an important role by restoring the ability of the 
gene to be expressed, which is crucial if the gene is a tumor suppressor gene.  HDACs consist of 
four classes, spanning 18 isozymes.  Current HDAC inhibitors approved and in development are 
considered pan-inhibitors, blocking a wide array of HDAC isozymes, increasing the risk of 
adverse effects.  β-thujaplicin is derived from the heartwood of trees in the cupressaceae family 
and from it is derived the troplone scaffold.  The tropolone scaffold involves several advantages 
over other classes of HDAC inhibitors, such as various positions in which diverse functional 
groups can attach and thus can direct specificity to certain HDAC isozymes.  Herein we describe 
our efforts to develop compounds at the α-position of the tropolone scaffold as well as 
preliminary biologic data.  
 
Introduction: 
In eukaryotic cells, DNA is contained in a condensed and tightly packed structure called 
chromatin.  Structural modification of chromatin may occur by adding acetyl groups, which 
neutralize positively charged lysine residues in the chromatin.  This causes the chromatin to 
become loosely packed and as a result permits the DNA to be accessible for gene transcription.  
Consequently, removing the acetyl group from chromatin compacts the complex and stops gene 
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expression.  Histone deacetylase (HDAC) is an enzyme that removes the acetyl group to restore 
the positive charges on the lysine residues and thus suppresses gene transcription, potentially 
causing cancer since inappropriate silencing of tumor suppressor genes can lead to tumor 
formation.  Therefore, inhibitors of HDAC play an important role in stopping the progression of 
cancer by expressing the silenced gene1. 
The mechanism of antitumor activity of HDAC inhibitors is not entirely clear.  Theories 
include dysregulation of genes involved in cell cycle progression, differentiation, and apoptosis.  
HDAC inhibitors appear to be effective against hematological and epithelial tumor sources by 
having a role in cell cycle arrest, apoptosis, antiangiogenesis.  The effect that occurs from HDAC 
inhibitor treatment appears to be dependent on the tumor cell rather than the specific HDAC 
inhibitors used1.  
HDAC inhibitors are currently being explored in the treatment of stomach, colorectal, 
and renal cancers.  Annually, there are about 217,000 new cases and 82,000 deaths that result 
from these cancers2,3.  Surgical treatment is the main mode of therapy for treating these types of 
cancer making it important to find a pharmacologic option that can improve the quality of life of 
patients and decrease healthcare costs4.  
HDACs are a family of enzymes that consist of four major classes that differ in their 
structure and function.  Classes I, II, and IV are metalloenzymes that contain a zinc component 
of the active site and are targeted by the HDAC inhibitors currently in development for anti-
cancer activity1.  Class III HDACs are considered sirtuins and are all NAD+-dependent 
proteases5.  They are not inhibited by classical (class I, II, IV) inhibitors but are inhibited by 
nicotinamide, also known as vitamin B31.  Among the classes of HDACs, there are 18 different 
isozymes, 11 of which are metalloenzymes6.  
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Inhibitors of HDAC classes I, II, and IV can be differentiated into four main groups of 
compounds: small molecule hydroxamates, cyclic tetrapeptides, benzamides, and short-chain 
fatty acids5.  These four classes can be generalized by having a common pharmacophore, which 
is essential for the interaction with the enzyme.  This pharmacophore incorporates a hydrophobic 
cap that hinders access to the active site, a polar site, and a hydroxamic acid type zinc-binding 
site1.  The zinc-binding site is separated by a hydrophobic spacer with optimal length that spans 
the hydrophobic pocket of the enzyme1. 
Hydroxamic acids are the largest class of HDAC inhibitors.  Compounds containing 
hydroxamic acid residues bind to the HDAC catalytic site with high affinity, blocking access of 
the substrate to the zinc ion.  Compounds of this class are very potent but are reversible 
inhibitors of HDAC classes I, II, and IV.  Trichostatin A (TSA) was one of the first hydroxamic 
acids developed but was found to be toxic and lack specificity. This led to the development of 
suberoylanilide hydroxamic acid (SAHA), also known as vorinostat, a second-generation 
compound currently approved for the treatment of cutaneous T-cell lymphoma that causes cell 
growth arrest, differentiation, and/or apoptosis.  Hydraxamic acids, as well as benzamides, are 
the focus of development for new compounds as these compounds have a better HDAC 
inhibitory profile and lower toxicity risk compared to other classes of HDAC inhibitors1. 
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Importance of Current Project   
The inhibitor compounds of class I, II, and IV in development have exhibited toxicity, 
creating the need of developing HDAC inhibitor compounds specific to certain HDAC enzymes 
in order to decrease the prevalence of toxicity.  Current HDAC inhibitor compounds in clinical 
trials are considered to be active against a range of HDAC isozymes and have demonstrated 
toxicity, likely related to the inhibition of the many functions of HDAC isozymes.  Ideally 
inhibitors should be designed for activity against specific HDAC isozymes in order to improve 
efficacy and reduce toxicity.  Class I isozymes, which include HDAC 1, 2, 3, and 8, tend to be 
over-expressed in certain tumors, such as HDAC 2 in colon cancer, and correlate with poor 
prognosis.  Class II, which include HDAC 4, 5, 6, 7, 9, and 10 have been correlated with better 
prognosis.  Mice knockout experiments of HDAC 3, 5, and 9 show adverse cardiac toxicity 
indicating that inhibitors that target these isozymes may cause toxicity.  Thus, it appears that 
designing a class I inhibitor compound, especially one with activity against HDAC 1, 2 or 8, 
would be an attractive strategy6. 
 β-thujaplicin, is a natural product isolated from the heartwood of trees in the 
cupressaceae family in the early 1950s.  It has been shown to have activity against melanoma 
and prostate cancer cell lines and a related compound, α-thujaplicin, has demonstrated activity 
against lymphocytic leukemia and stomach cancer lines.  β-thujaplicin is 
characterized by a low molecular weight and allows for structural 
modification6.  
Derived from β-thujaplicin is the tropolone scaffold, which is a 
unique structure that allows for both potency and selectivity.  The 
scaffold allows for a zinc metal binding portion (the α-hydroxy ketone), a lipophilic seven-
	  	  	  5	  
membered ring that interacts with the hydrophobic pocket surrounding the zinc ion via three 
possible positions: α, β, γ.  These unique positions allow for substitution to reach important 
pockets in the HDAC isozyme6. 
 Compared to hydroxmates, an alternative class of HDAC inhibitors based on the 
tropolone scaffold may yield several advantages.  While both classes include a metal-targeting 
moiety, the tropolone class possesses important distinctions in terms of metabolic stability and 
isozyme selectivity.  Hydroxamates, such as vorinostat, have relatively short metabolic half-lives 
as a result of an easily reduced N-O bond, a hydrolytically labile amide linkage and the 
formation of glucoronides.  In comparison, the metal-targeting moiety of the tropolone class 
would not be at risk of reductive or hydrolytic transformations due to its vinylogous carboxylic 
acid.  Another unique advantage for the tropolone is that it’s scaffold offers multiple points of 
variation and access to pockets in proximity to the metal binding site that may impart isozyme 
selectivity, thereby reducing toxicity and increasing efficacy6.  
 
Results and Discussion: 
As β-substituted compounds have previously been reported by our research group7, the 
goal of this project is to optimize the α-position of the tropolone scaffold by placing groups with 
diverse functionality through late stage analog synthesis.  Thus we needed to develop an efficient 
synthetic route that would allow for development of numerous analogs.   
We initially developed a 5-step synthesis (scheme 1) to obtain our tropolone analogs. Our 
synthesis began with the esterification of commercially available tropolone 1 with iodomethane 
by following the procedure reported by Koodanjeri, et al8 to produce methyl protected tropolone 
2. 
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The purpose was to add an easily removable hydroxyl protecting group on the tropolone 
in order to be able to add desired substituents in the α-position. The next step was to add a 
halogen on the tropolone ring in order to run Suzuki cross-coupling reactions.  Bromine was the 
halogen of choice due to its increased reactivity towards palladium insertion and this was 
achieved by use of N-bromosuccinamide and carbon tetrachloride.  We witnessed excess 
bromination at this step, and careful purification with silica gel column chromatography was 
required to obtain 3.  The last step of de-protecting the methyl group proved to be difficult as our 
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conditions of HBr and acetic acid were not able to yield the final product.  Conditions of BBr3 
and CH2Cl2 did not work as well. 
  Since the problem was in the de-protecting step, we decided to try adding other 
protecting groups besides methyl, such as methoxymethyl, that would allow for Suzuki coupling 
reactions but would also be easy to remove for the hydrolysis to the final product.  However, 
these other attempts proved to be unsuccessful at obtaining the intermediary products as the less 
stable protecting groups rapidly decomposed and thus we were unable to proceed to the Suzuki 
coupling reactions. 
 After these attempts, we developed an alternative route as seen in scheme 2 to obtain our 
tropolone derivatives based on a protocol previously reported for the synthesis of α-thujaplicin9.  
Starting from a commercially available chlorotropone 6, we were able to immediately run Suzuki 
cross-coupling reactions in order to prepare a series of lipophilic compounds with substitutions at 
the α-position 7a-e and thus this route cut a step from our original synthesis in scheme 1.  After 
coupling the desired groups, the addition of hydrazine led to the corresponding 7-aryl 2-amino 
tropones 8a-e. Final hydrolysis of the amino-tropones under basic conditions yielded the α-
substituted tropolones 5a-e in good overall yield.   
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We then aimed to add substituents that would have extended lipophilic chains.  Since our 
synthetic route in scheme 2 was effective, we used it to add our desired groups on, with slight 
modification.  As our desired groups were aliphatic chains, we ran our palladium couplings 
utilizing grignard reagents in Kumada cross-coupling conditions.  The coupling and subsequent 
hydrazine reactions achieved our desired derivatives but the hydrolysis step did not yield our 
final product.  Upon NMR analysis of the final product, it appeared that our product did not 
hydrolyze in place of the hydrazine and it is theorized that it instead pulled an allylic proton on 
the aliphatic linker 10.  The proposed mechanism can be seen below (9-11), whereas the 
potassium trapped enolate extinguished the system’s reactivity.  Realizing this problem would 
apply to our other aliphatic linker compounds, we tried our synthesis using the bromo-methoxy 
material in scheme 1 to avoid this problem in the hydrolysis step.  Unfortunately, due to the 
basicity of the grignard reagents, the kumada coupling conditions yielded a Favorskii 
rearrangement.  Thus, we were forced to change our conditions and we decided to try to use 
Suzuki couplings with boronic acids.   
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But to continue with the original scheme 1, we determined we needed an alternative de-
protection method in order to obtain the final analog.  We tried various basic conditions such as 
KOH, H2SO4, Na2O2, and LiOH, all leading to failed attempts.  Eventually we found in the 
literature the LiCl in DMF conditions.  However, we noticed that LiCl worked except for groups 
that had an alkene in the aliphatic linker as the chlorine would insert in the alkene of the aliphatic 
chain.  The proposed mechanism can be seen in 12-15. 
 
 
 
To overcome this we decided to buy terminal boronic acids and then hydrogenate the 
intermediates after the coupling to avoid the chance of LiCl insertion.  The nucleophilic de-
protection scheme with of LiCl then worked to de-protect the methyl group and we were able to 
develop five more compounds (scheme 3).  
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Our next efforts were focused on producing compounds that had extended aromatic 
chains.  When looking for more commercially available boronic acids, we found 4-
Bromophenylboronic acid.  We recognized this as a potential tropolone derivative and as well as 
a building block, since we could couple to the boronic acid and then run another Suzuki coupling 
to substitute the bromine with another group.  We decided to use the synthesis route seen in 
scheme 1 for this group of analogs as it was more efficient.  The bromo-methoxy route would 
allow for a large-scale build up of intermediates and allow for late stage synthetic elaboration to 
construct the desired analogs.   
Scheme 3.
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 Using our now modified route with an improved LiCl de-protection step, we were able to 
obtain the desired final compounds but we discovered a few issues.  The first was that upon 
NMR analysis, the proton peaks showed the compound with some impurity in the aromatic 
region.  Liquid chromatography mass spectroscopy (LCMS) showed that along with our product, 
we had multiple homo-coupled para-bromo impurities 16.  We theorize this to be due to excess 
boronic acid being able to couple to the bromide on the newly coupled para-bromo tropone.  To 
overcome this issue, we initially decreased the equivalents of the boronic acid to 1.5 and then 
eventually to 0.9.  We found that the 1.5 equivalents had less of the poly-coupled para-bromo 
compound compared to the 2 equivalents but that 0.9 equivalents had minimal of this impurity 
with a relatively smaller yield.  Thus, we thus changed our reaction conditions to 0.9. 
The next problem was the significant grease peaks in the 0-1 range in the proton NMR.  
This was consistent with all compounds we made and only at the final step of the synthesis.  We 
theorized that either the reaction conditions caused some decomposition of the compound since 
we ran the reaction at 160°C or there were some impurities in the LiCl or the DMF.  We changed 
our LiCl, DMF, and glass vials in which reactions ran, but still found grease in the NMR 
analysis.   
Thinking that the de-protection reaction of LiCl had some role in the grease issue, we 
then switched to another de-protection method from the literature using methanol/H2O. Since we 
found that this method was free of grease and since this method involves recrystallization instead 
of purifying the compound with silica gel column chromatography, we hypothesize that the 
grease was due to our compound stripping some binders from the silica gel column 
chromatography.  Having overcome these problems, we were able to produce more analogs as 
seen in scheme 4. 
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Biological Data:  
In order to learn more about the structure activity relationship of our compounds and 
tailor future work to develop compounds with isozyme specificity and potent biological activity, 
we tested our compounds against various HDAC isozyme lines (table 1) and various cell lines 
(table 2).   
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Table 1. Inhibition of HDAC Isozymes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
We tested our first five analogs developed at the α-position as well as some of the 
previously reported β-substituted compounds (20a-f, 21)7 to compare their biologic activity 
 HDAC Isozyme (Ki values in nM) 
Compound 1 2 8 4 5 6 
TSA 0.87 1.06 69.65 14,547 4,120 3.02 
5a NA 0.26 1.09 NA NA 527 
5b NA 0.25 186.30 NA NA NA 
5c NA 0.81 83.80 NA NA NA 
5d NA 0.42 811.50 NA NA NA 
5e NA 0.23 123.65 NA NA NA 
20a NA 0.06 1.47 10,860 NA NA 
20b NA 0.12 2.38 8,361 NA NA 
20c NA 0.51 266.30 11,204 NA NA 
20d NA 0.13 12.81 806.13 NA NA 
20e NA 0.22 2.27 6115 NA NA 
20f NA 0.04 122.70 990.23 NA NA 
β-thujiplicin NA 15.44 177.95 NA NA NA 
21 NA NA 7.87 11,641 NA NA 
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against the various HDAC isozymes.  We tested these compounds by use of Michaelis-Menten 
analysis of six different HDAC isozymes: 1, 2, 4, 5, 6, and 86.  These results show that a few 
analogs have very good biological activity in two different HDAC isozymes (2 and 8) from 
HDAC class I and that both our α- and β-substituted tropolones function as potent inhibitors of 
HDAC 2.  As seen in table 1, seven of our compounds demonstrate high levels of selectivity 
(greater than 100-fold) for the inhibition of HDAC isozyme 2 compared to HDACs 1, 4, 5, 6, 
and 8.  Besides β-thujaplicin, all hydrolyzed compounds were more potent inhibitors of HDAC2 
than TSA, which exhibits pan-HDAC inhibition.  Compared to free tropolones, methylated 
tropolone 21 shows significantly lower activity, indicating that the ionizable α-hydroxy ketone 
may facilitate strong zinc chelation of the HDAC active site.   
Interestingly, some of the compounds (5a, 20a, 20b, and 20e) included HDAC 8 
inhibition at lower Ki values than those of both TSA and vorinostat at 69.95 and 480 nM, 
respectively.  The results also indicate that increasing steric bulk at the α-position was associated 
with loss of potency whereas increasing steric bulk at the β-position showed variable effects 
against HDAC 8. 
Knowing that our compounds had excellent activity against HDAC2, we wanted to see if 
this translated to cellular effects (table 2), thus judging their potential as drug candidates.  Since 
it has been established that HDAC inhibitors have anti-proliferative effects against hematological 
cancer cell lines, we tested our compounds against two T-cell lymphocyte lines: HuT078 and 
Jurkat6.  We also chose a colon cancer cell line, HCT116, and a pancreatic cancer cell line, 
BxPC-3) to test activity in solid tumor lines.  
 
 
	  	  	  15	  
 
Table 2. Inhibition of Cell Growth 
 
 
 
 
 
 
 
 
 
 
 
 
Tropolone analogs 5c, 5d, 20a and 20e showed significant half maximal growth 
inhibition (GI50) in both hematological T-lymphocyte cell lines.  Additionally, these compounds 
showed increased activity relative to vorinostat against the Jurkat cell line, having GI50 values 
less than 1 mM.  In the HCT-116 line, tropolones were less active but two derivatives, 5a and β-
thujaplicin, showed GI50 values less than 20 µM.  Similarly, in the BxPC-3 cells, 5b, 5d, 20a and 
β-thujaplicin had GI50 values less than 20 µM. 
We also tested our compounds against a non-malignant human dermal fibroblast line to 
assess toxicity of our compounds on normal cells.  The results indicated a lack of general 
cytotoxicity with our compounds, with most derivatives showing no activity at 100 µM.  This 
 Cell Line (GI50 values in mM) 
Compound Jurkat HuT-78 HCT-116 BxPC-3 hDF 
5a 3.33 7.83 15.24 29.39 96.46 
5b 1.15 4.11 32.06 17.1 93.07 
5c 0.62 2.87 56.99 35.93 >100 
5d 0.76 3.05 46.65 14.1 >100 
5e 1.86 4.74 34.98 21 >100 
20a 0.67 4.14 53.44 18.5 >100 
20b 4.62 8.95 43.67 91.6 >100 
20c 5.89 17.09 >100 34.79 >100 
20d 4.45 13.11 62.61 43.02 >100 
20e 0.59 3.25 26.86 104 >100 
20f 6.30 11.36 >100 180 >100 
β-thujiplicin 1.10 4.99 6.92 19 >100 
21 >100 >100 >100 >100 >100 
Vorinostat 0.90 2.10 2.50 5.56 18.95 
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value is significantly greater compared to vorinostat, indicating that our tropolones require 
higher concentrations in order to notice cytoxic effects.   
Recently, our compounds have been screened in mouse-derived organoids to assess its 
ability as preventative colon cancer agents.  These organoids are multicellular crypt-like 
structures that are derived from adult intestinal stem cells, embryonic stem cells, or induced 
pluripotent stem cells and can function as a tissue surrogate.  The organoid included cells that 
possessed Math1 is a transcription factor that regulates secretory cell differentiation as well as a 
more mature differentiation marker, Muc2.  Compounds that enhance differentiation and 
increase Math1 expression may have chemo-preventative properties.  It is believed that reduced 
expression of Math1 may result in cancer development due to suppression of growth-regulating 
differentiation pathway or by allowing the tissue more susceptible to inflammation from reduced 
production of mucus.  Broad-spectrum HDAC inhibitors, TSA and vorinostat, were found to 
increase commitment to the secretory cell lineage by increasing both Math1 and Muc2.  Our 
compounds increased Math1 with minimal Muc2 effect, which the authors’ attributed to the 
selectivity of our compounds10. 
 
Conclusion  
This project describes our efforts to develop selective and potent histone deacetylase 
inhibitors at the based on the unique tropolone scaffold as potential anti-cancer drug candidates.  
Our work focused on the α-position in order to optimize the structure activity relationship for 
that position.  We tested the biologic activity for some of our compounds and they appear to be 
selective and have good activity against HDAC isozymes 2 and 8.   
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Currently our project still remains ongoing as we continue to produce α-substituted 
compounds and learn more about the ideal structure activity relationship of these HDAC 
compounds.  Ideally, our second and third set of compounds will be tested for biological activity 
in order to compare to our first set of compounds to further outline the direction of the project.  
Some ongoing works to increase our library of analogs include making aniline, heterocycles, and 
sulfonamide analogs.  We also started some initial work on γ-substituted compounds but more 
focus is needed to find an efficient synthetic route to develop these analogs.  Our group intends 
to have multi-substituted analogs to increase specificity to and activity against various HDAC 
isozymes. 
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Experimentals: 
 
 
General Procedure For Suzuki Couplings: 2-Chloro-2,4,6-cycloheptatrien-1-one (1.0 eq), aryl boronic 
acid (2.0 eq), and cesium carbonate (4.0 eq) were added to 10:1 THF/H2O (0.2 M) and the mixture was 
thoroughly degassed by bubbling argon through solution (10 min). Bis(triphenylphosphine)palladium(II) 
dichloride (0.1 eq) was added and the mixture was again degassed with argon (5 min). The homogenous 
solution was heated at 75 °C for 16 h before being cooled to room temperature. Water was added and the 
mixture was extracted with EtOAc (3 x). The combined organic layers were washed with brine, dried over 
Na2SO4, filtered and concentrated in vacuo. Flash chromatography of the crude residue (SiO2, EtOAc in 
hexanes) provided the desired 2-aryl-tropones. 
 
 
 
2-phenyl tropone 2a: 99 % yield; Rf = 0.5 (1:1 EtOAc:Hexanes); Mp = 77.9-79.2 °C; IR (KBr): ν: 3101, 
3022, 1895, 1808, 1625, 1547, 1441, 1261, 784, 698. 1H NMR (500 MHz, CDCl3) δ 7.51-7.49 (m, 2H), 
7.43-7.36 (m, 4H), 7.20 (d, J = 12.2 Hz, 1H), 7.14 (ddd, J = 19.8, 1.3, 1.3, 1.3, 1.4 Hz, 1H), 7.07-7.03 (m, 
1H), 6.99-6.95 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 186.4, 152.4, 142.2, 139.9, 136.5, 135.2, 133.7, 
133.2, 129.0, 128.3, 128.0. HRMS (ESI) calcd for C13H11O [M+H]+: 183.0810; found: 183.0788. 
 
 
2-naphthyl tropone 2b: 98 % yield isolated with inseparable impurity that is removed during amination; 
Rf = 0.58 (1:1 EtOAc:Hexanes); Mp = N/A; IR (KBr): ν: 3056, 3009, 2359, 1926, 1876, 1771, 1703, 1626, 
1574, 800, 777, 733, 697. 1H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 1.45 Hz, 1H), 7.90 (d, J = 2.0 Hz, 
1H), 7.71 (d, J = 8.3 Hz, 1H), 7.57-7.45 (m, 3H), 7.41 (dd, J = 6.9, 0.85, 0.90 Hz, 1H), 7.38-7.36 (m, 1H), 
7.26 (d, J = 12.1 Hz, 1H), 7.20-7.16 (m, 1H), 6.99-6.97 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 186.4, 
152.6, 141.7, 138.3, 137.6, 135.5, 133.8, 133.5, 133.2, 130.7, 128.3, 128.2, 126.4, 125.9, 125.6, 125.2, 
125.2. HRMS (ESI) calcd for C17H13O [M+H]+: 233.0966; found: 233.0945. 
 
 
 
2-(4-methoxy-phenyl) tropone 2c: 99 % yield; Rf = 0.59, (1:1 EtOAc:Hexanes); Mp = 52.2-53.6 °C; IR 
(KBr): ν: 2958, 2835, 2541, 2041, 1974, 1883, 1622, 1564, 1175, 1031, 830, 780, 686. 1H NMR (500 
MHz, CDCl3) δ 7.51 (d, J= 2.0 Hz, 1H), 7.50 (d, J = 2.0 Hz, 1H), 7.40 (d, J = 9.0 Hz, 1H), 7.23 (d, J = 
12.1 Hz, 1H), 7.15 (ddd, J = 21.5, 1.2, 1.2, 1.2, 1.2 Hz, 1H), 7.06 (t, J = 20.0, 10.1, 9.5 Hz, 1H), 6.99-6.94 
	  	  	  20	  
(m, 3H), 3.85 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 186.5, 159.9, 152.0, 142.0, 136.0, 135.3, 133.8, 
132.8, 132.1, 130.6, 113.6, 55.3. HRMS (ESI) calcd for C14H13O2 [M+H]+: 213.0916; found: 213.0898. 
 
 
 
2-(2,5-methoxy-phenyl) tropone 2d: 96 % yield; Rf = 0.29 (1:1 EtOAc:Hexanes); Mp = 102.2-103.2 °C; 
IR (KBr): ν: 2940, 2832, 2351, 1628, 1588, 1218, 1046, 808, 748, 694. 1H NMR (500 MHz, CDCl3) δ 
7.30 (dd, J = 8.4, 1.0, 1.1 Hz, 1H), 7.15-7.13 (m, 2H), 7.03-6.94 (m, 2H), 6.88 (s, 1H), 6.88 (s, 1H), 6.82 
(t, J = 3.2, 1.6, 1.6 Hz, 1H), 3.79 (s, 3H), 3.74 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 186.5, 153.7, 150.9, 
150.3, 141.0, 136.3, 134.9, 133.5, 133.3, 130.9, 116.4, 114.1, 112.5, 56.5, 55.7. HRMS (ESI) calcd for 
C15H15O3 [M+H]+: 243.1021; found: 243.1016. 
 
 
 
2-(2,3,4-methoxy-phenyl) tropone 2e: 91 % yield; Rf = 0.29 (1:1 EtOAc:Hexanes); Mp = 98.3-99.6 °C; 
IR (KBr): ν: 2946, 2841, 2825, 1947, 1883, 1626, 1583, 1458, 1103, 1072, 1013, 799, 684. 1H NMR (500 
MHz, CDCl3) δ 7.28 (dd, J = 9.6, 1.1, 1.1 Hz, 1H), 7.18-7.12 (m, 2H), 7.03-6.93 (m, 3H), 6.72 (d, J = 8.5 
Hz, 1H), 3.89 (s, 3H), 3.88 (s, 3H), 3.82 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 187.0, 154.2, 150.7, 
150.6, 141.9, 140.6, 136.3, 135.1, 133.6, 133.1, 127.7, 124.6, 107.3, 60.9, 60.7, 56.0. HRMS (ESI) calcd 
for C16H17O4 [M+H]+: 273.1127; found: 273.1118. 
 
General Procedure For α-Amination of 2-aryl tropone: To a solution of α-aryl-tropone (1.0 eq) in 
EtOH (0.2 M) was added 65 % hydrazine monohydrate (25 eq). The solution was allowed to stir at room 
temperature until all starting material was consumed by monitoring on TLC (~45 min). The reaction was 
concentrated in vacuo and then taken up in EtOAc (0.05 M) and washed with H2O (3 x). The organic 
layer was then washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. Flash 
chromatography of the crude residue (SiO2, EtOAc in hexanes) provided the desired α-amino-tropones. 
 
 
 
7-amino-2-phenyl tropone 3a: 88 % yield; Rf = 0.61 (4:1 EtOAc:Hexanes); Mp = 209.3-210.4 °C; IR 
(KBr): ν: 3403, 3251, 3122, 1604, 1515, 1428, 1336, 1235, 1054, 919, 686. 1H NMR (500 MHz, CD2Cl2) 
δ 7.50-7.38 (m, 5H), 7.33 (t, J = 14.4, 7.1, 7.3 Hz, 1H), 7.14 (t, J = 20.2, 10.1, 10.1 Hz, 1H), 6.93 (d, J = 
10.0 Hz, 1H), 6.77 (t, J = 19.6, 9.8, 9.8 Hz, 1H), 6.12 (s, 2H). 13C NMR (126 MHz, CD2Cl2) δ 174.9, 
158.5, 143.4, 142.5, 139.0, 135.8, 130.1, 128.3, 127.7, 123.4, 112.7. HRMS (ESI) calcd for C13H12NO 
[M+H]+: 198.0919; found: 198.0900. 
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7-amino-2-naphthyl tropone 3b: 89 % yield; Rf = 0.63 (4:1 EtOAc:Hexanes); Mp = 221.7-222.5 °C; IR 
(KBr): ν: 3443, 3280, 3150, 1604, 1511, 1446, 1062, 780, 737. 1H NMR (500 MHz, CD2Cl2) δ 7.90 (d, J 
= 8.2 Hz, 1H), 7.87 (d, J = 8.3 Hz, 1H), 7.55-7.45 (m, 4H), 7.38-7.35 (m, 2H), 7.23 (td, J = 20.2, 10.1, 
10.1, 1.1, 1.1, 1.1 Hz, 1H), 6.98 (d, J = 9.9 Hz, 1H), 6.80 (t, J = 19, 9.5, 9.5 Hz, 1H), 6.13 (s, 2H). 13C 
NMR (126 MHz, CD2Cl2) δ 175.2, 157.9, 141.8, 141.8, 139.6, 136.5, 134.0, 132.2, 128.8, 128.1, 126.9, 
126.4, 126.3, 126.2, 126.1, 123.2, 112.8. HRMS (ESI) calcd for C17H14NO [M+H]+: 248.1075; found: 
248.1065. 
 
 
 
7-amino-2-(4-methoxy-phenyl) tropone 3c: 87 % yield; Rf = 0.55 (4:1 EtOAc:Hexanes); Mp = 153.8-
155.2 °C; IR (KBr): ν: 3434, 3269, 3233, 2962, 1601, 1511, 1450, 1244, 1023, 829, 781. 1H NMR (500 
MHz, CD2Cl2) δ 7.49 (dd, J = 9.6, 1.0, 0.9 Hz, 1H), 7.44-7.41 (m, 2H), 7.10 (td, J = 20.0, 1.0, 1.0, 1.0 Hz, 
1H), 6.96-6.93 (m, 2H), 6.89 (d, J = 10.0 Hz, 1H), 6.24 (s, 2H), 3.83 (s, 3H). 13C NMR (126 MHz, 
CD2Cl2) δ 174.9, 159.5, 158.4, 141.9, 138.7, 135.6, 135.4, 131.3, 123.3, 113.7, 112.9, 55.8. HRMS (ESI) 
calcd for C14H14NO2 [M+H]+: 228.1025; found: 228.1018. 
 
 
 
S13 7-amino-2-(2,5-methoxy-phenyl) tropone 3d: 84 % yield; Rf = 0.39 (4:1 EtOAc:Hexanes); Mp = 
109.6-110.7 °C; IR (KBr): ν: 3278, 3191, 2939, 2831, 1601, 1519, 1455, 1219, 1047, 783, 725. 1H NMR 
(500 MHz, CD2Cl2) δ 7.39 (d, J = 9.5 Hz, 1H), 7.12 (t, J = 20.2, 10.1, 10.1 Hz, 1H), 6.92-6.87 (m, 3H), 
6.80 (d, J = 2.9 Hz, 1H), 6.72 (t, J = 19.5, 9.7, 9.8 Hz, 1H), 6.42 (s, 2H), 3.77 (s, 3H), 3.69 (s, 3H). 13C 
NMR (126 MHz, CD2Cl2) δ 174.5, 158.1, 154.1, 151.5, 139.8, 138.9 136.2, 133.9, 122.6, 117.1, 113.4, 
112.9, 112.6, 56.7, 56.2. HRMS (ESI) calcd for C15H16NO3 [M+H]+: 258.1130; found: 258.1151. 
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7-amino-2-(2,3,4-methoxy-phenyl) tropone 3e: 86 % yield; Rf = 0.42 (4:1 EtOAc:Hexanes); Mp = 
175.3-176.5 °C; IR (KBr): ν: 3367, 2939, 2825, 1599, 1514, 1455, 1097, 1019, 770. 1H NMR (500 MHz, 
CDCl3) δ 7.41 (d, J = 9.5 Hz, 1H), 7.09 (t, J = 20.1, 10.0, 10.1 Hz, 1H), 6.91 (d, J = 8.5 Hz, 1H), 6.87 (d, J 
= 10 Hz, 1H), 6.72-6.68 (m, 2H), 6.28 (s, 2H), 3.99 (s, 3H), 3.87 (s, 3H), 3.73 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 174.4, 157.2, 153.1, 151.3, 142.0, 139.3, 138.7, 135.4, 129.7, 124.5, 122.4, 112.4, 107.4, 
60.9, 60.7, 55.9. HRMS (ESI) calcd for C16H18NO4 [M+H]+: 288.1236; found: 288.1217. 
 
General Procedure For α-amino-2-aryl tropone Hydrolysis: α-amino-2-aryl tropone (1.0 eq) was 
dissolved in 1:1 EtOH:H2O (2.0 M) to which was added 2 N KOH (20 eq). The reaction was heated to 
100 °C and stirred for 16 h. The reaction was returned to room temperature and diluted with 15 % NaOH. 
The aqueous layer was washed with Et2O (3 x) and CH2Cl2 (3 x) and then acidified to pH 2.0 and 
extracted with CH2Cl2 (3 x) washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. 
 
 
S14 α-phenyl tropolone 4a: 90 % yield; Rf = 0.52 (1:19 iPrOH:CH2Cl2); Mp = N/A; IR (KBr): ν: 3200-
2800 broad, 2917, 2848, 1721, 1712, 1615, 1595, 1548, 1417, 1247, 737, 698. 1H NMR (500 MHz, 
CD2Cl2) δ 7.60 (d, J = 9.9 Hz, 1H), 7.51 (d, J = 7.4 Hz, 2H), 7.46 (t, J = 14.8, 7.2, 7.6 Hz, 2H), 7.42-7.39 
(m, 3H), 7.10 (t, J = 17.2, 7.7, 9.5 Hz, 1H). 13C NMR (126 MHz, CD2Cl2) δ 171.9, 170.8, 141.1, 140.7, 
139.5, 137.3, 129.8, 128.7, 128.6, 127.9, 122.0. HRMS (ESI) calcd for C13H11O2 [M+H]+: 199.0759; 
found: 199.0749. 
 
 
 
α-naphthyl tropolone 4b: 91 % yield; Rf = 0.52 (1:19 iPrOH:CH2Cl2); Mp = N/A; IR (KBr): ν: 3200-
2800 broad, 3173, 3044, 2925, 1614, 1593, 1548, 1470, 1367, 1258, 1242, 1210, 800, 773, 689. 1H NMR 
(500 MHz, CD2Cl2) δ 7.96 (d, J = 7.3 Hz, 2H), 7.61-7.50 (m, 6H), 7.44 (t, J = 14.0, 6.9, 7.1 Hz, 2H), 7.13-
7.09 (m, 1H). 13C NMR (126 MHz, CD2Cl2) δ 171.6, 170.8, 141.6, 138.6, 138.2, 137.2, 134.1, 131.5, 
129.0, 128.9, 127.8, 127.0, 126.7, 126.5, 126.0, 125.9, 123.8. HRMS (ESI) calcd for C17H13O2 [M+H]+: 
249.0916; found: 249.0928. 
 
 
 
α-(4-methoxy-phenyl) tropolone 4c: 92 % yield; Rf = 0.52 (1:19 iPrOH:CH2Cl2); Mp = N/A; IR (KBr): ν: 
3200-2800 broad, 3128, 3927, 1920, 1802, 1615, 1593, 1499, 1367, 1039, 802, 728. 1H NMR (500 MHz, 
CD2Cl2) δ 7.49 (d, J= 10.0 Hz, 1H), 7.42-7.39 (m, 3H), 7.22 (dd, J = 7.4, 1.5, 1.5 Hz, 1H), 7.07-7.02 (m, 
3H), 3.76 (s, 3H). 13C NMR (126 MHz, CD2Cl2) δ 171.2, 170.9, 157.1, 141.4, 137.5, 136.5, 130.7, 130.1, 
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129.8, 127.4, 122.6, 121.0, 111.7, 56.1. HRMS (ESI) calcd for C14H13O3 [M+H]+: 229.0865; found: 
229.0854. 
 
 
 
α-(2,5-methoxy-phenyl) tropolone 4d: 89 % yield; Rf = 0.52 (1:19 iPrOH:CH2Cl2); Mp = N/A; IR (KBr): 
ν: 3200-2800 broad, 2930, 2832, 2002, 1925, 1797, 1615, 1595, 1548, 1496, 1398, 1201, 1044, 1024, 
805, 728. 1H NMR (500 MHz, CD2Cl2) δ 7.49 (d, J = 10 Hz, 1H), 7.39-7.37 (m, 2H), 7.07-7.03 (m, 1H), 
6.97-6.92 (m, 2H), 6.82 (d, J = 2.7 Hz, 1H), 3.79 (s, 3H), 3.71 (s, 3H). 13C NMR (126 MHz, CD2Cl2) δ 
171.1, 170.9, 154.1, 151.3, 141.3, 137.6, 136.3, 130.7, 127.4, 122.6, 116.7, 114.4, 112.9, 56.8, 56.2. 
HRMS (ESI) calcd for C15H15O4 [M+H]+: 259.0970; found: 259.0956. 
 
 
 
α-(2,3,4-methoxy-phenyl) tropolone 4e: 89 % yield; Rf = 0.55 (1:19 iPrOH:CH2Cl2); Mp = N/A; IR 
(KBr): ν: 3200-2800 broad, 2994, 2938, 2837, 1992, 1920, 1713, 1614, 1596, 1408, 1301, 1108, 1046, 
793, 735. 1H NMR (500 MHz, CD2Cl2) δ 7.49 (d, J = 10 Hz, 1H), 7.40-7.36 (m, 2H), 7.07-7.01 (m, 1H), 
6.93 (d, J = 8.6 Hz, 1H), 6.77 (d, J = 8.6 Hz, 1H), 3.89 (s, 3H), 3.89 (s, 3H), 3.74 (s, 3H). 13C NMR (126 
MHz, CD2Cl2) δ 171.9, 170.4, 154.6, 151.8, 142.7, 141.4, 173.3, 136.8, 127.5, 127.4, 124.8, 122.2, 107.8, 
61.4, 61.1, 56.5. HRMS (ESI) calcd for C16H17O5 [M+H]+: 289.1076; found: 289.1103. 
 
 
 
